Fosun Pharmaceutical Signs Deal With Neuracle to Buy Alzheimer's Drug Rights
MT Newswires Live
Jul 29
Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196), through unit Fosun Pharma Industrial, entered into a license agreement with neuroscience research company Neuracle for Alzheimer's drug AR1001, according to a Shanghai bourse on Tuesday.
The Chinese pharmaceutical company will obtain the rights to develop, register, manufacture, and market the drug within the mainland, Hong Kong, and Macau.
Fosun will pay up to 150 million yuan, which includes an upfront payment of 40 million yuan and regulatory milestones of up to 110 million yuan.
The company's Shanghai and Hong Kong shares both rose 2% during late morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.